Pharming Group NV has published the transcript of its Q3 2025 earnings call, which took place on November 6, 2025. The event was attended by key members of Pharming's management team, including the Chief Executive Officer, Chief Commercial Officer, Chief Medical Officer, and Chief Financial Officer, as well as analysts from major financial institutions. During the call, management reported strong financial results, highlighting a 30% year-over-year revenue growth for the third quarter and an operating profit of US$15.8 million-nearly four times higher than the previous year. Additionally, operating cash flow reached US$32 million, nearly restoring the company's cash position to pre-acquisition levels following the purchase of Abliva. Looking ahead, management emphasized the rapid progress of Pharming's product pipeline: "Our high-value pipeline is advancing rapidly, with a clear objective to deliver two potential blockbuster assets, creating meaningful value creation catalyst for shareholders." The company also noted steps taken to enhance financial discipline, including optimizing G&A headcount for efficient capital allocation. Leadership changes were also announced, with the company welcoming a new Chief Commercial Officer to drive commercial growth and expressing gratitude to the outgoing executive for nine years of service. The full transcript can be accessed through the link below.